Tackling neurodegenerative diseases represents a formidable challenge for our ageing
society. Recently, major achievements have been made in understanding the molecular …

Over the past 15 years neurotrophic factors have generated considerable excitement for
their potential as therapy for a wide variety of degenerative neurological disorders, for which …

Bcl-2 and Bcl-XL prevent neuronal apoptosis during development, neurodegenerative
disease, and trauma. To test a new anti-apoptosis strategy for neuroprotection, we …

Clinical trials in amyotrophic lateral sclerosis (ALS) have been conducted for over half a
century now and have incorporated a wide variety of drugs. Most of these trials have had …

The goals of this review are to summarize some of the novel observations on the genetic
and molecular basis of enteric nervous system disorders, with particular emphasis on the …

Until 10 years ago, the genetic basis of Charcot–Marie–Tooth (CMT) disease was largely
unknown. With the finding of an intrachromosomal duplication on chromosome 17 in 1991 …

The mechanisms of motor neuronal death in amyotrophic lateral sclerosis (ALS) remain to
be unclear. Phosphatidy-linositol 3-kinase (PI3-K) and its main downstream effector …

Leukemia inhibitory factor (LIF) is a survival factor for motoneurons. In this study we
investigated whether intense systemic LIF therapy prevents the loss of lumbar motoneurons …

INTRODUCTION: Use of mechanical ventilation (MV), administered either invasively via
tracheostomy, or more commonly non-invasively (CPAP, BiPAP), appears to be increasing …

Troglitazone (TGZ), an antidiabetic drug that improves insulin‐resistance in the peripheral
tissues, was tested for neurotrophic activity in motoneurones and other neurones in culture …